- Home
- DSGN vs PRQR Comparison
DSGN vs PRQR Comparison
Compare DSGN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- PRQR
- Stock Information
- Founded
- DSGN 2017
- PRQR 2012
- Country
- DSGN United States
- PRQR Netherlands
- Employees
- DSGN N/A
- PRQR N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- PRQR Health Care
- Exchange
- DSGN Nasdaq
- PRQR Nasdaq
- Market Cap
- DSGN 208.9M
- PRQR 244.4M
- IPO Year
- DSGN 2021
- PRQR 2014
- Fundamental
- Price
- DSGN $5.26
- PRQR $2.26
- Analyst Decision
- DSGN
- PRQR Strong Buy
- Analyst Count
- DSGN 0
- PRQR 8
- Target Price
- DSGN N/A
- PRQR $8.88
- AVG Volume (30 Days)
- DSGN 141.5K
- PRQR 290.0K
- Earning Date
- DSGN 08-07-2025
- PRQR 08-07-2025
- Dividend Yield
- DSGN N/A
- PRQR N/A
- EPS Growth
- DSGN N/A
- PRQR N/A
- EPS
- DSGN N/A
- PRQR N/A
- Revenue
- DSGN N/A
- PRQR $20,129,184.00
- Revenue This Year
- DSGN N/A
- PRQR N/A
- Revenue Next Year
- DSGN N/A
- PRQR N/A
- P/E Ratio
- DSGN N/A
- PRQR N/A
- Revenue Growth
- DSGN N/A
- PRQR 8.65
- 52 Week Low
- DSGN $2.60
- PRQR $1.07
- 52 Week High
- DSGN $7.77
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- PRQR 58.27
- Support Level
- DSGN $4.68
- PRQR $1.98
- Resistance Level
- DSGN $5.60
- PRQR $2.27
- Average True Range (ATR)
- DSGN 0.39
- PRQR 0.15
- MACD
- DSGN 0.04
- PRQR 0.02
- Stochastic Oscillator
- DSGN 79.95
- PRQR 89.32
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.